Organizing and participating many international/regional multicenter studies on pharmacological agents and interventional devices, with high visibility in international academic community

A registration study for primary and secondary prevention in dyslipidemic Taiwanese. The databank could be availabe for the researchers to conduct feasibility studies prior to clinical trials.

− Global leading PI, steering committee member, Advisory board (Evolocumab、Ranolazine、vericiguat、Edoxaban、Idarucizumab、BRILINTA、Trajenta、Coralan) − Great contribution to any disorder, drug − Involved in or cooperated with international organizations, conferences

•Research focuses on the genetics of inheritable cardiac diseases including long QT syndrome, Brugada syndrome, CPVT, early repolarization syndrome, idiopathic VF and many kinds of cardiomyopathies (ex. Hypertrophic cardiomyopahty) etc. I published >130 SCI papers in the international journals. I am also involved in more than 20 global clinical trials for more than 15 years, and published papers. •With an academic record dedicated to the field of cardiomyopathy and heart failure, he was invited as a key candidate from Taiwan and served as a steering committee member for both trials. •He was elected by the scientific committee of European Society of Cardiology (the largest cardiologic socienty in the world as top 100 cardiologists who contributed to the cardiologic field in 2024. •Establish a Genetic Heart Disease Center in 2024